Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial.
about
Ivabradine -- the first selective sinus node I(f) channel inhibitor in the treatment of stable angina.Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization.Cellular mechanisms underlying the pharmacological induction of phosphenesEffectiveness of Ivabradine in Treating Stable Angina PectorisRecent advances in treatment of heart failureAddressing Major Unmet Needs in Patients with Systolic Heart Failure: The Role of IvabradineIvabradine, coronary artery disease, and heart failure: beyond rhythm controlCurrent medical management of chronic stable anginaEfficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable anginaComparison of the efficacy and tolerability of ivabradine and ranolazine in patients of chronic stable angina pectorisHeart rate and use of beta-blockers in stable outpatients with coronary artery diseaseGenetics of sick sinus syndromeManagement standards for stable coronary artery disease in India.Ivabradine in combination with Beta-blockers in patients with chronic stable angina after percutaneous coronary intervention.Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials.Ivabradine for the treatment of stable angina pectoris in octogenarians.Long-term outcomes of ivabradine in inappropriate sinus tachycardia patients: appropriate efficacy or inappropriate patients.ANMCO/GICR-IACPR/SICI-GISE Consensus Document: the clinical management of chronic ischaemic cardiomyopathyIvabradine, a novel treatment for clozapine-induced sinus tachycardia: a case series.Ivabradine: the evidence of its therapeutic impact in angina.Treatment of refractory anginaThe Contribution of HCN4 to normal sinus node function in humans and animal modelsI(f) channel inhibitor ivabradine lowers heart rate in mice with enhanced sympathoadrenergic activities.Chronotropic Modulation of the Source-Sink Relationship of Sinoatrial-Atrial Impulse Conduction and Its Significance to Initiation of AF: A One-Dimensional Model Study.Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study.Use-dependent inhibition of hHCN4 by ivabradine and relationship with reduction in pacemaker activity.Economic evaluation of trimetazidine in the management of chronic stable angina in GreeceNovel blockers of hyperpolarization-activated current with isoform selectivity in recombinant cells and native tissueBeta-Adrenergic blockers as antiarrhythmic and antifibrillatory compounds: an overview.Molecular Mapping of Sinoatrial Node HCN Channel Expression in the Human HeartDrug insight: If inhibitors as specific heart-rate-reducing agents.Safety and efficacy of oral ivabradine as a heart rate-reducing agent in patients undergoing CT coronary angiography.Evolving treatment strategies for chronic refractory angina.The pacemaker current: from basics to the clinics.Absence of respiratory effects with ivabradine in patients with asthma.Selective heart rate reduction with ivabradine slows ischaemia-induced electrophysiological changes and reduces ischaemia-reperfusion-induced ventricular arrhythmias.Preserved Autonomic Cardiovascular Regulation With Cardiac Pacemaker Inhibition: A Crossover Trial Using High-Fidelity Cardiovascular Phenotyping.Ivabradine: a new strategy for management of stable angina.Ranolazine in patients with coronary artery disease.Utility of ranolazine in chronic stable angina patients.
P2860
Q24544613-1C1D5E71-81DC-4CC3-87A1-19B29815C633Q24605881-A8BC8043-60E0-4A83-B784-B3D977BC08E2Q24681601-8E5314CA-10EF-4983-B6A9-94B1A2F1E627Q26750710-2DBB863D-CCC1-4E6F-A752-A4A3C622D397Q26766223-2F071201-19C6-477F-BDF3-BC0CD46BCEEEQ26773370-A8B8A8C9-A971-42FC-887C-C77D1DC5A823Q26865770-573CA9FD-6C57-4F7C-928B-2647F417A7BBQ28213164-27F6A1B4-F73D-42B1-A3D2-99CA3C11967CQ28276346-C05986E0-8F95-40BA-B606-0511B83FA704Q28706249-CF30CC4A-18F5-41BF-BAF2-DCA8F8F29F56Q28730142-BD13F85C-D953-4DD9-A0D6-48EF9EC38567Q28741053-FC813637-BF0B-4435-9FC4-CCC992E49EE7Q30239853-AAB73C2C-D7BD-4ACF-8DD3-D08C09CAD2C3Q30316766-9BFAD778-C891-404E-BFE1-56228D83DEB3Q30608315-D978DE5C-E133-4E2A-9414-6697B8E82AC5Q33159163-B09B712F-730D-47D6-8401-4C777E60580BQ33162534-D66ED1EA-E434-47D8-92BF-2226A0E2A82FQ33647497-7007410F-665A-4F49-B2A4-3CABC39A1278Q33937346-EC98C303-408F-4DCC-8088-1241709A6E76Q33973963-877EC87D-8C79-424A-BE87-B76418EA8AAFQ34986448-AC48D2A5-7B2E-4E0D-A8A0-8BB2C856C02BQ35005962-EB7CE642-C147-4C3F-9DEA-A6E3254AAFBAQ35047088-A50CE19F-F566-423A-902B-FFB98935319DQ35851594-A3466E23-9630-40E6-A4F8-8E4F881AB996Q35873307-56B26B84-FCA7-48F6-9ACC-6C214E5E50D4Q36052500-CE4E04DA-3063-4D1F-BDC1-1C58F4502A8EQ36146507-5493320F-112F-4E2B-8867-6FF4B2502A0EQ36159185-524783C6-917E-49C1-BBB8-12C792EF309AQ36167681-D69CAD2F-74D0-4193-BF04-C35A15B9A7B4Q36200432-1769D2D9-80D3-4167-AEBF-5C6DC9E8F2C7Q36304200-25D2F1E6-A493-4FB1-A16D-E9CF47D78A1CQ36361206-67F5CA72-4FAD-4D27-A6D4-D515E3DDF09EQ36382563-0E733BDB-03E2-486D-B454-26E9DB731E51Q36729727-DC309529-01C3-469E-94AA-EFA07C1BCFE2Q36792707-E339D943-A132-42FD-9F57-708A22EB8B19Q36844601-39E9528E-2174-474C-A4D2-4407D507971EQ36877742-4DF73948-5345-4873-AA1D-E88DBDB0C521Q36886149-E211D83C-DF4A-4E1E-88D1-8BCC222758A6Q36916931-55BED0AB-E9D8-4B0F-805D-A791ECB3353DQ37004023-59B72B86-5A35-4E79-A09B-32C9AB2F1E95
P2860
Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Antianginal and antiischemic e ...... red, placebo-controlled trial.
@en
Antianginal and antiischemic e ...... red, placebo-controlled trial.
@nl
type
label
Antianginal and antiischemic e ...... red, placebo-controlled trial.
@en
Antianginal and antiischemic e ...... red, placebo-controlled trial.
@nl
prefLabel
Antianginal and antiischemic e ...... red, placebo-controlled trial.
@en
Antianginal and antiischemic e ...... red, placebo-controlled trial.
@nl
P2093
P1433
P1476
Antianginal and antiischemic e ...... red, placebo-controlled trial.
@en
P2093
Guy Lerebours
Ivabradine Investigators Group
Jeffrey S Borer
Patrice Jaillon
P304
P356
10.1161/01.CIR.0000048143.25023.87
P407
P577
2003-02-01T00:00:00Z